Why is big Pharma getting out of antibacterial drug discovery?

Current Opinion in Microbiology

Volumn 6, Issue 5, 2003, Pages 427-430

  Projan, Steven J ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID;

ANTIMICROBIAL THERAPY; DRUG APPROVAL; DRUG MANUFACTURE; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; REVIEW;

EID: 0242291985     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2003.08.003     Document Type: Note

References (10)

1. Fauci AS: Infectious diseases: considerations for the 21st century. Clin Infect Dis 2001, 32:675-685.
2. Ahmad M, Urban C, Mariano N, Bradford PA, Calcagni E, Projan SJ, Bush K, Rahal JJ: Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999, 29:352-355.
3. Stein A, Raoult D: Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002, 35:901-902.
4. US Food and Drug Administration. Labeling requirements for systematic antibacterial drug products intended for human use. 21 CFR Part 201 Docket No. 00N-1463. 2003.
5. Dewan PK, Fry AM, Laserson K, Tierney BC, Quinn CP, Hayslett JA, Broyles LN, Shane A, Winthrop KL, Walks I et al.: Washington DC, anthrax response team. Inhalational anthrax outbreak among postal workers, Washington DC, 2001. Emerg Infect Dis 2002, 8:1066-1072.
6. Stewart JJ, Allison PN, Johnson RS: Putting a price on biotechnology - many bioentrepreneurs incorrectly estimate the value of their technology by failing to account adequately for the cost, risk, and time inherent in product development. Nat Biotechnol 2001, 19:813-817. This paper describes the derivation of net present value (NPV) and how it applies to the evaluation of biotechnology projects.
7. Projan SJ: New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr Opin Pharmacol 2002, 2:513-522.
8. Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold JB, Cramer JA, Margolis PS, Wang W, Koehn J, Wu C et al.: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother 2002, 46:2752-2764. An excellent description of the success of a target-based antibacterial drug discovery program targeting peptide deformylase.
9. Mandell LA, Ball P, Tillotson G: Antimicrobial safety and tolerability: differences and dilemmas. Clin Infect Dis 2001, 32(Suppl 1):S72-S79.
10. US Food and Drug Administration: IDSA/PhRma/FDA Working Group Meeting. Nov. 19-20, 2002. On World Wide Web URL: http://www.fda.gov/cder/present/idsaphrma/default.htm. The output of joint working group with representatives from the US FDA, the Infectious Diseases Society of American, large pharmaceutical companies and biotech companies discussing the key issues in clinical trials for novel antibacterial agents.